EP4701658A1 — Influenza virus vaccines

USPTO Abstract

The present invention is inter alia directed to immunogenic compositions for use in the treatment or prophylaxis of an infection with an Influenza virus, wherein the immunogenic composition comprises: (a) a first nucleic acid encoding a hemagglutinin (HA) antigen of a strain of a first subtype of Influenza A virus; (b) a second nucleic acid encoding a HA antigen of a strain of a second subtype of Influenza A virus; (c) a third nucleic acid encoding a HA antigen of a first strain of Influenza B virus; and (d) optionally, a fourth nucleic acid encoding a HA antigen of a second strain of Influenza B virus, wherein an immune response is elicited against HA antigens of said strains of first and second subtypes of Influenza A virus, said first and, optionally, second strains of Influenza B virus and at least one further HA antigen subtype of Influenza A virus, being different from any of the HA antigen subtypes of Influenza A virus encoded by a nucleic acid present in the composition.